Advertisement

Orthopädie & Rheuma

, Volume 22, Issue 4, pp 39–42 | Cite as

HIV-Infektion, HAART und Osteoporose

Von den Leitlinien vergessen

  • Thomas SeppelEmail author
  • Klaus M. Peters
Fortbildung HIV und Osteoporose

Die HIV-Infektion weist heute bei adäquater Behandlung einen überwiegend chronischen Charakter auf. Umso mehr treten Folgeerkrankungen in den Vordergrund. Typische skelettassoziierte Komplikationen der HIV-Infektion sind Osteopenie/Osteoporose, Osteomalazie und Osteonekrosen. Da HIV-Infektion und HAART als Risikofaktoren bisher in der DVO-Leitlinie zur Osteoporose keine Erwähnung finden, sollte man sich bei Diagnostik und Therapie an den internationalen Empfehlungen orientieren.

Literatur

  1. 1.
    Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N Lawson-Ayayi S, Mehsen N et al. Reduced bone mineral desity in HIV-infected patients: Prevalence and associated factors. AIDS 2008;22:395–402CrossRefGoogle Scholar
  2. 2.
    Maffezzoni F, Porcelli T, Karamouzis I, Quiros-Rolda E, Castelli F, Mazziotti G, Giustina A. Osteoporosis in Human Immunodeficiency Virus patients — an emerging clinical concern. Eur Endocrinol 2014;10:79–83CrossRefGoogle Scholar
  3. 3.
    Shiau S, Broun EC, Arpadi SM, Yin MT. Indident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS 2013;27:1949–57CrossRefGoogle Scholar
  4. 4.
    Torti C, Mazziotti G, Soldini PA, Foca E, Maroldi R, Gotti D, Carosi G, Giustina A. High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 2012;41:512–7CrossRefGoogle Scholar
  5. 5.
    Ilha TASH, Comim FV, Copes RM, Compston JE, Premaor MO. HIV and vertebral fractures: a systematic review and metaanalysis. Sci Rep 2018;8:7838CrossRefGoogle Scholar
  6. 6.
    Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS 2011;3:53–9Google Scholar
  7. 7.
    Dong HV, Cortes YI, Shiau S, Yin MT. Osteoporosis and fractures in HIV/Hepatitis C virus coinfection: A systematic review and metaanalysis. AIDS 2014;28:2119–31CrossRefGoogle Scholar
  8. 8.
    Ahmad AN, Ahmad SN, Ahmad N. HIV infection and bone abnormalities. The Open Orthopaedics Journal 2017;11:777–84CrossRefGoogle Scholar
  9. 9.
    McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrvandi GM, Cardoso SW, Santana JL, Brown TT. Bone Disease in HIV Infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937–46CrossRefGoogle Scholar
  10. 10.
    Borderi M, Davide G, Vescini F, De Crignis E, Cimatti L Biagetti C, Tampellini L, Re MC. Metabolic bone disease in HIV infection. AIDS 2009;23:1297–310CrossRefGoogle Scholar
  11. 11.
    Castronuovo D, Cacopardo B, Pinzone MR, Di Rosa M, Martelotta F, Schioppa O, Moreno S, Nunnari G. Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci 2013;18:2413–9Google Scholar
  12. 12.
    Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010;26:48–53CrossRefGoogle Scholar
  13. 13.
    Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, Yin MT, Powderly WG. Recommendations for evaluation an management of bone disease in HIV. Clin Infect Dis 2015;60:1242–51CrossRefGoogle Scholar
  14. 14.
    Grant PM, Kitch D, McCommsey GA, Dube MP, Haubrich R, Huang J, Riddler S Tebas P, Zolopa AR, Collier AC, Brown TT. Low baseline CD4+ count is associated with greater bone density loss after antiretroviral therapy initiation. Clin Infect Dis 2013;57:1483–8CrossRefGoogle Scholar
  15. 15.
    Hileman CO, Overton ET, MCComsey GA. Vitamin D and bone loss in HIV. Curr opin HIV AIDS 2016;11:277–84CrossRefGoogle Scholar
  16. 16.
    Negredo e, Domingo P, Perez-Alvarez N, gutierrez M, Puig J, Munoz J, Mateo G, Bonjoch A, Redondo E, Clotet B. Multicenter randomized study to assess changes in HIV subjects with low bone mineral density after switching from tenfovir to abacavir: osteo TDF study. 20th Conference on Retroviruses and opportunistic infections. March 3-6, 2013. Atlanta, GA. Abstract 824Google Scholar
  17. 17.
    Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronante on bone turnover and bone density for at least five years in HIV-infected men. J Clin Endocrinol Metab 2012;97:1922–8CrossRefGoogle Scholar
  18. 18.
    Rozenberg S, Lanoy E, Bentata M, et al. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses 2012;28:972–9CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.MönchengladbachDeutschland
  2. 2.

Personalised recommendations